We have one goal; to cure Angelman syndrome.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
We have one goal; to cure Angelman syndrome.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
Are you newly diagnosed? We can help. We can help.
Are you newly diagnosed? We can help. We can help.
What is Angelman syndrome? (AS)
Angelman syndrome (AS) is a rare genetic condition that affects the nervous system, leading to challenges with movement, balance, and communication. It is caused by changes to chromosome 15, which impact brain function.
Advancing Hope, Driving Discovery
Translating science into life-changing therapies
At FAST, our mission is simple yet urgent: to accelerate meaningful therapies and, ultimately, a cure for Angelman syndrome. We believe in harnessing scientific rigor, community strength, and bold partnerships to transform research into real-life outcomes for families. With every grant, collaboration, and trial, we move closer to turning hope into impact.
people worldwide estimated to be living with AS
distinct therapeutic programs initiated
invested since 2011
Who Are We Helping?
Behind every research grant and clinical trial are the faces of those we serve — children learning new skills, families finding connection, and adults with Angelman syndrome gaining independence. Our mission is centered on improving quality of life now while driving forward the science that will change the future.
Latest News
- Industry
On October 8, 2026, ASF and FAST hosted a webinar with Ultragenyx after the announcement that their phase 3 trial for GTX-102 (aspire) did not meet primary or key secondary
- Fundraising
Before Sonia and her son José set off on Peru’s Inca Trail this September, their guides gave the group two goals: survive first, and finish if you can. For Sonia
- Industry
Read the press release
- Research
At INSYNC-AS 2026, researchers came together to examine how genes beyond UBE3A and differences within UBE3A itself may shape Angelman syndrome and future therapeutic development. Why can Angelman syndrome (AS)
- Industry